ABVC BioPharma postponed the previously announced distribution of ordinary shares in its subsidiary, BioKey (Cayman), Inc., from August 3 to August 21, 2026. The company cited the need for additional time to complete administrative, regulatory, and tax-related matters. The record date remains July 24, 2026, and the distribution ratio is unchanged at 0.169464 BioKey shares per ABVC share. The prior ex-dividend date will be revised once finalized. This biotechnology company develops therapies for rare diseases.

ABVC BioPharma postponed its previously announced distribution of ordinary shares in BioKey (Cayman), Inc., originally scheduled for August 3, 2026. The delay allows the company additional time to finalize administrative, regulatory, and tax-related matters required to complete the transaction. The distribution ratio remains fixed at 0.169464 BioKey shares for each ABVC common share held as of the unchanged record date. The prior ex-dividend date is voided, with new dates to be announced once logistics are resolved. ABVC BioPharma operates in the biotechnology industry, focusing on drug discovery and development.